Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis
Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis
In the past ten years, newer drugs with more selective affinity for the alpha-receptor have
 been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation
 alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely.
 This retrospective comparison is intended to be a priliminary comparison of their
 effectiveness and side effects.
Inclusion Criteria:

 -  Males age 45-80 years

 -  Diagnosis of prostate cancer

 -  Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker
 therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation

 -  Baseline AUA score< or =12

 -  May be on antiandrogenand/or alpha reductase therapy

 -  Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the
 primary therapy for prostate cancer with curatives intent -

 Exclusion Criteria:

 -  History of insulin-dependent diabetes

 -  Uncontrolled hypertention

 -  History of symptomtic hypotension (including syncope and dizziness)

 -  Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary
 Retention

 -  Pre-existing prostatitis either continuous or intermittent

 -  Concurrent use of any other anticholinergics

 -  previous or concurrent usage of LHRH agonist